TY - JOUR
T1 - Primary cutaneous melanomas seen as inflamed pigmented lesions in patients undergoing adjuvant interferon treatment
T2 - A possible diagnostic clue for physicians
AU - Hu, Stephanie
AU - Kim, Caroline C.
AU - Jessup, Chad
AU - Phung, Thuy L.
AU - Curiel-Lewandrowski, Clara
PY - 2009/5
Y1 - 2009/5
N2 - Background: In addition to a complete skin examination every few months, adjuvant interferon treatment is often recommended for patients with high-risk melanomas. Therefore, dermatologists play an important role in detecting multiple primary melanomas and may be required to attempt to identify the primary melanoma in patients with metastatic disease. Observations: We describe 3 patients with a diagnosis of melanoma who were diagnosed as having a new primary cutaneous melanoma within weeks of initiating interferon treatment. All 3 melanomas were inflamed clinically, prompting excisional biopsy. Histopathologic analysis of the melanomas revealed thin (<1.0 mm Breslow thickness) invasive tumors, as well as the presence of tumor-infiltrating lymphocytes and/or regression. Conclusions: Inflamed melanocytic lesions in patients undergoing interferon treatment should be further evaluated to investigate the possibility of primary cutaneous melanomas. This observation may enable earlier detection and treatment of melanomas in patients with multiple tumors or metastatic melanoma with an unknown primary site.
AB - Background: In addition to a complete skin examination every few months, adjuvant interferon treatment is often recommended for patients with high-risk melanomas. Therefore, dermatologists play an important role in detecting multiple primary melanomas and may be required to attempt to identify the primary melanoma in patients with metastatic disease. Observations: We describe 3 patients with a diagnosis of melanoma who were diagnosed as having a new primary cutaneous melanoma within weeks of initiating interferon treatment. All 3 melanomas were inflamed clinically, prompting excisional biopsy. Histopathologic analysis of the melanomas revealed thin (<1.0 mm Breslow thickness) invasive tumors, as well as the presence of tumor-infiltrating lymphocytes and/or regression. Conclusions: Inflamed melanocytic lesions in patients undergoing interferon treatment should be further evaluated to investigate the possibility of primary cutaneous melanomas. This observation may enable earlier detection and treatment of melanomas in patients with multiple tumors or metastatic melanoma with an unknown primary site.
UR - http://www.scopus.com/inward/record.url?scp=66149083937&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=66149083937&partnerID=8YFLogxK
U2 - 10.1001/archdermatol.2009.38
DO - 10.1001/archdermatol.2009.38
M3 - Article
C2 - 19451501
AN - SCOPUS:66149083937
SN - 0003-987X
VL - 145
SP - 565
EP - 568
JO - Archives of Dermatology
JF - Archives of Dermatology
IS - 5
ER -